STAT+: Hims’ sales miss as telehealth competition grows

STAT PlusNewsletterThe Readout Hims’ sales miss as telehealth competition grows Bristol’s partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine ChenMay 12, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. My colleagues today launched a series investigating one of the biggest public health crises in the U.S. — the alcohol epidemic. Their stories will examine factors ranging from the influence of the alcohol industry to the gaps in treatment options for addiction. Read part 1 of the series here.Advertisement The need-to-know this morning Rigel Pharma will market the newly approved breast cancer drug Veppanu under a commercialization agreement signed with Arvinas and Pfizer. Roche received European clearance for a new blood test to detect early Alzheimer’s disease. BridgeBio submitted an application to the FDA seeking approval of its drug encaleret to treat patients with autosomal dominant hypocalcemia type 1, or ADh2, a rare genetic disease that causes low calcium levels in the blood. Bristol turns to Chinese drugmaker for early-stage pipeline restock Bristol Myers Squibb this morning announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs, the latest and a notably large case of a global pharmaceutical company looking to China for its next medicines, my colleague Andrew Joseph reports. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech May 12, 2026 STAT Plus: Capsida says it still doesn’t know what caused gene therapy death The Readout May 11, 2026 STAT Plus: Astellas treatment offers new hope to a devastated rare disease community Advertisement Health May 11, 2026 STAT Plus: Five years after disaster, a rare disease community gets new chance at treatment Exclusive May 11, 2026 STAT Plus: Medicare is spending far less than expected on new Alzheimer’s drugs Biotech May 8, 2026 The biotechs wear Prada Subscriber Picks